joining us now from no novo nordisk you are still looking for a slower growth rate does this come down to pricing pressure >> we have seen a strong momentum if you look at international race all geographies outside the u.s. grew we see a very strong growth. i'm very optimistic in how we came out of 2019 and momentum we'll have in 2020 where we'll rollout the portfolio. i'm very optimistic for 2020 >> i just want to ask you something else you've introduced a tablet to offset the pressure. do you think that this is the way insulin is moving going forward to circumvent traditional pricing products like coming out with alternative products like these tablets? >> you are right we have patent windows where we can recoup our innovation. as you mention, this tablet is the first time ever to make a large molecule available in a tablet get it into the stomach and into the blood to reduce blood glucose. this is a benefit for patients who are used to injecting themselves so that is breakthrough innovation for us. >> thank you for that detail interesting topic indeed esg has become an increasingly

let's get back to earnings and novo nordisk hitting the tape. red lion seeing 2020 operating profit growing at constant fx. that is the mainline to look at. it said its launch in the usa is off to a good start. it sees a 2020 share buyback of up to 17 billion danish krone and 48 ebit. andestimate was 2.4 billion it came in at 2.8 billion. for your sales, 122 billion danish krone. speak to the will ceo of novo nordisk, the world's largest insulin maker. 9:30 a.m. london time. we have numbers from a chip maker. this is very much about the global appetite for tech and chips. up city and not only beats, but gives higher guidance on actual numbers. the fiscal first quarter, 297 million profit. when they talk about sales for the guidance for the year, they see sales 3% to 7% higher. that first-quarter total segment beat the highest of the slate.es we had on the when it comes to the second torter margin guidance, 14 14.6% and we see the full-year margin at 16%. i want to tie that together because what i am seeing from china, it constitutes a quarter of

novo nordisk sees profit gains. some of the other pharmaceuticals are rising.ok at the downside, you see imperial brands down more than 5%. that is one of the companies with a profit warning today. we also had a profit warning from dansk a bank, but -- danske there andnestle is up siemens as well, down 1.7%. three is one of the top companies on the stoxx 600 that awayle to take more points from the index. european markets are being assess down as investors further efforts to contain the coronavirus. the markets with laura cooper in london. are we seeing drops today because of misses on earnings, or is the coronavirus coming back to take away gains we have seen over the last couple of sessions? laura: it is about coronavirus fears. we have seen this broad risk on sentiment yesterday driving a robust rally. i think the reality is beginning to sink in that yes, we are going to see a significant hit to economic growth and that is bubbling back. anna: interesting that we saw the asian session make gains, and the european session is weaker. are we mismatched because

. >> novo nordisk sees a modest increase in profit in 2020 with an expected rise of between one and 5%that is the world's biggest maker of diabetes drugs faces pressing challenges, especially in the u.s. does the coronavirus change everything? >> short-term, it does not. we have inventories in china. we manufacture for china in china and we have a supply chain where -- the key concern is to make sure we bring our medicines to patients. if you have diabetes and rely on insulin, that is a life-saving medicine, so it is important for us to make sure there is an intact supply chain. short-term, we feel good about that but into months and years, it becomes more challenging. short-term, we are in a solid place. ♪ ritika: you are watching "bloomberg best." i'm ritika gupta. effect of the coronavirus are being watched by governments around the world. a substantial slowdown would drag down demand and disrupt supply chain. a negative impact on europe's growth, european commissioner for economic and financial affairs spoke with guy johnson about the economic risks posed by the virus and what the

nestle, novo nordisk, big companies, big heavyweights at the top weighing the most on the index.lacking in a direction at the open. we are at record levels in terms of risk asset prices. do you think that is justified by the current economic situation? >> i think it is too early to tell. this is not particularly high. if the cases looked like they are going more global, that can have an impact. it is too early to tell at this point. we are not making too many changes to the portfolio on the back of it. anna: we are asking executives about the impact of the coronavirus. not telling us what they're expecting to do. burberry told us the impact it is having on sales. and what was open. and what impact they were seeing. details?etting enough >> not at the moment. it is very hard to tell. we have a number of tech companies within the fund. the supply chain has become so compact. they are not seeing shortages right now. but they are worried they will start to see shortages. have met are i trying to be transparent. anna: they have their own stockpiles. >> exactly. hard to see where indus

italy. .ollow results from ferrari wednesday, earnings are announced by pharmaceutical gskanies novo nordisknd as well as bnp paribas. anna: we have not even got to thursday at. a slew of earnings across different industries. highlights include the banking ,ector results from socgen, ing and unicredit. plus watch out for total and ecuador. -- equinor. friday, maybe we get a rest. let's get a first word news update. >> oil demand has plunged by 20%. executive described the scale of the demand caused by the coronavirus outbreak. it dropped by 3 million barrels a day, the largest amount since the financial crisis. opec and its allies are considering how to respond. eu,u.k. may have left the but the battle over brexit does not look like it's going away anytime soon. boris johnson is using a speech in london to walk away from talks. he does not want to sign up for the single market regulation or the ruling of top courts. he says britain will prosper with or without a deal. president trump's impeachment trial is drawing to a close. senators are preparing to acquit the president. lamar alexander su

it happens with live tv beaming across the world, but we will get more from the novo nordisk chief executivepecially when it comes to currency swings. coming up, we will discuss the outlook for your cake real estate. we speak with the chief executive officer of luxury property developer. that is coming up next, and this is bloomberg. ♪ francine: this is "bloomberg surveillance." let's get straight to the bloomberg business flash in new york city with viviana hurtado. ,iviana: so for this year shares are continuing their parabolic surge, in two days rising 36 percent it gives tesla a market value greater and general motors. fiat chrysler, and volkswagen combined. other is up20 no even a quarter as much. on the owner of the new york stock exchange and a continental exchange saying it approached ejb to deal. but the ark asked the market aace did not engage in marketable way. a potential deal could value ebay at $30 billion. ryanair being told to drop ads claiming is europe's greenest carrier. the u.k. advertising watchdog says the statement is misleading, unsubstantiated, and based partly on al